ALPS Medical Breakthroughs ETF (SBIO) |
| 51.56 -0.5 (-0.96%) 02-27 15:59 |
| Open: | 51.855 |
| High: | 51.855 |
| Low: | 51.08 |
| Volume: | 10,662 |
| Market Cap: | 138(M) |
| PE Ratio: | 0 |
| Exchange: | New York Stock Exchange Arca |
| Industry: | Asset Management |
| Sector: | Financial Services |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 54.13 |
| Resistance 1: | 52.12 |
| Pivot price: | 51.13 |
| Support 1: | 48.88 |
| Support 2: | 40.67 |
| 52w High: | 54.79 |
| 52w Low: | 22.33 |
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Fri, 27 Feb 2026
(SBIO) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Thu, 19 Feb 2026
This Biotech ETF Is a Catalyst-Rich Story - ETF Trends
Sun, 15 Feb 2026
(SBIO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Thu, 29 Jan 2026
Biotech M&A Wave Positions SBIO for Growth - ETF Database
Tue, 06 Jan 2026
Can ETF Winners of Q4 of 2025 Rally in Q1 of 2026? - Nasdaq
Wed, 24 Dec 2025
ALPS ETFs in Biotech and Commodities Lead 2025 Gains - ETF Database
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
